PMID- 32998905
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 105
IP  - 11
DP  - 2021 Nov
TI  - Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated 
      disorder other than optic neuritis: a systematic review.
PG  - 1591-1598
LID - 10.1136/bjophthalmol-2020-317267 [doi]
AB  - BACKGROUND/AIMS: Optic neuritis (ON) is the primary ophthalmic manifestation of 
      myelin oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD), but numerous 
      reports have expanded the visual manifestations of this condition. The goal of 
      this study was to synthesise the extensive literature on this topic to help 
      ophthalmologists understand when testing for MOG-IgG should be considered. 
      METHOD: A systematic review of the English-language literature was performed 
      according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
      guidelines and searches were conducted using Ovid MEDLINE (from January 1, 1948 
      to April 1, 2020) and Ovid EMBASE (from January 1, 1947 to April 1, 2020). 
      Inclusion criteria included studies describing non-isolated ON ophthalmic 
      manifestations where cell-based assays were used for the detection of MOG 
      antibodies. RESULTS: Fifty-one articles representing 62 patients with a median 
      age of 32.0 (range 2-65), female gender (51%) and follow-up of 20.0 months 
      (range: 1-240) were included. Twenty-nine patients had non-isolated ON afferent 
      visual manifestations: uveitis, peripheral ulcerative keratitis, acute macular 
      neuroretinopathy, neuroretinitis, venous stasis retinopathy, large preretinal 
      macular haemorrhage, orbital inflammatory syndrome, orbital apex syndrome, optic 
      perineuritis, papilloedema and homonymous visual field defects. Incomplete 
      recovery of ON was associated with a case of Leber's hereditary optic neuropathy. 
      Efferent ophthalmic manifestations included cranial neuropathies, internuclear 
      ophthalmoplegia, central nystagmus, saccadic intrusions and ocular flutter. 
      Cranial nerve involvement was secondary to enhancement of the cisternal portion 
      or brainstem involvement. All included cases were treated with corticosteroids 
      with 31% of cases requiring additional immunosuppressive therapy. CONCLUSIONS: 
      MOGAD has been associated with various afferent and efferent ophthalmic 
      manifestations apart from isolated ON. Awareness of these findings may result in 
      earlier diagnosis and treatment.
CI  - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Vosoughi, Amir R
AU  - Vosoughi AR
AD  - Max Rady College of Medicine, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, Canada.
FAU - Ling, Jennifer
AU  - Ling J
AUID- ORCID: 0000-0002-0547-1085
AD  - Faculty of Medicine, University of British Columbia, Vancouver, Canada.
FAU - Tam, Kenneth T
AU  - Tam KT
AUID- ORCID: 0000-0001-7342-0418
AD  - Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, 
      Canada.
FAU - Blackwood, Jayden
AU  - Blackwood J
AD  - Faculty of Arts and Science, University of Toronto, Toronto, Canada.
FAU - Micieli, Jonathan A
AU  - Micieli JA
AUID- ORCID: 0000-0003-4911-9152
AD  - Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, 
      Canada jmicieli@kensingtonhealth.org.
AD  - Division of Neurology, Department of Medicine, University of Toronto, Toronto, 
      Canada.
AD  - Kensington Vision and Research Centre, Toronto, Canada.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200930
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
SB  - IM
MH  - Autoantibodies
MH  - Female
MH  - Humans
MH  - Immunoglobulin G
MH  - Myelin-Oligodendrocyte Glycoprotein
MH  - *Optic Neuritis/diagnosis
MH  - Papilledema
MH  - Vision Disorders
OTO - NOTNLM
OT  - Optic Nerve
OT  - Visual pathway
COIS- Competing interests: None declared.
EDAT- 2020/10/02 06:00
MHDA- 2022/03/04 06:00
CRDT- 2020/10/01 05:29
PHST- 2020/06/24 00:00 [received]
PHST- 2020/09/05 00:00 [revised]
PHST- 2020/09/06 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2020/10/01 05:29 [entrez]
AID - bjophthalmol-2020-317267 [pii]
AID - 10.1136/bjophthalmol-2020-317267 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2021 Nov;105(11):1591-1598. doi: 
      10.1136/bjophthalmol-2020-317267. Epub 2020 Sep 30.